Adrian brings extensive experience as a chairman and chief executive across technology and life sciences companies. He also served as a partner at Boundary Capital Partners.
Oshen Holdings led the Series A round with backing from DSW Ventures, SFC Capital, and Boundary Capital.
"I would like to thank all our investors for their trust and support. Our success in continuing to raise investment despite the difficult market conditions over the last few years is testament to their belief in the company’s commercial potential and our world-class team. The funds will be used to complete the pre-clinical testing of our first medical device product range and our preparations for entry into the orthopaedic market."
The oversubscribed raise was led by investment platform Wealth Club alongside existing backers Deepbridge Capital and Boundary Capital.
"Glyconics offers a transformational, cost-efficient, rapid and non-invasive approach to diabetes screening – and it is testament to this pioneering device and all at Team Glyconics that this raise was so significantly over-subscribed. We are delighted to be continuing with our existing investors and, of course, welcome our new investors from Wealth Club and other private investors to the fold."
The investment round was led by Praetura Capital with backing from Boundary Capital Partners and other investors.
"The UK alone spends £3.1bn on treating chronic wounds each year, while the US spends $50bn. Add to this the significant escalation in costs, not to mention the considerable distress to patients and families if the only course of treatment for non-healing wounds is amputation. It’s clear that there’s a real need for innovation in this area."
.png)
